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Abstract 
 
Tetrahydropentagamavunon-0 (THPGV-0) is assumed to be main 
metabolite product of biotransformation process of PGV-0. THPGV-0 was 
synthesized by converting PGV-0 to the compound by hydrogenation with Pd/C 
as a catalyst. PGV-0 potently inhibited the histamine release from rat mast cells 
in vitro and in vivo, however, ironically only traces amount of compound was 
found in the blood. THPGV-0 is assumed to have important roles in the biological 
effects of PGV-0 in vivo. In present study, we investigated the antiallergy effect 
of THPGV-0 in compare to this of PGV-0 in vitro. The study was performed by 
using rat basophilic leukemia (RBL-2H3) cell line, a tumor analog of mucosal 
mast cells. DNP-BSA, an antigen, was used as an inducer for stimulating the 
histamine release from mast cells. In present study, THPGV-0 at low 
concentration did not succeed to inhibit the histamine release, but at higher 
concentration (30 and 100 M) showed strong effects. THPGV-0 at concentration 
of 100 M depleted the histamine release by 96.10 0.51%. In compare to  
PGV-0, THPGV-0 has higher efficacy but less potent. In the study, the 
possibilities of the spontaneous release from RBL-2H3 cells by the compounds 
were also observed. All concentrations of THPGV-0 as well as PGV-0 showed low 
spontaneous histamine release, less than 10 % of the total histamine contained 
in RBL-2H3 cells. 
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Abstrak 
 
Tetrahidropentagamavunon-0 (THPGV-0) diperkirakan sebagai metabolit 
utama dari proses metabolisme PGV-0 dalam tubuh. THPGV-0 disintesis melalui 
hidrogenasi PGV-0 menggunakan katalis Pd/C pada suhu kamar. PGV-0 dapat 
menghambat pelepasan histamin dari sel mast secara poten pada penelitian in 
vitro maupun in vivo. Namun, PGV-0 hanya ditemukan dalam kadar yang sangat 
rendah dalam darah pada pemberian intravena maupun peroral. THPGV-0 
diduga mempunyai peran penting dalam aktivitas biologi PGV-0. Penelitian ini 
bertujuan untuk mempelajari efek antialergi THPGV-0 dibandingkan dengan 
PGV-0 secara in vitro. Penelitian ini menggunakan kultur sel RBL-2H3 yang 
kemudian dinduksi oleh DNP-BSA, suatu antigen. Hasil penelitian, THPGV-0 
konsentrasi rendah belum mampu menghambat pelepasan histamin, namun 
pada konsentrasi tinggi (30 and 100 M)  menunjukkan efek yang kuat dalam 
menghambat pelepasan histamin. THPGV-0 100 M secara kuat menghambat 
pelepasan histamin hingga 96,10 0,51%. THPGV-0 mempunyai efikasi lebih 
tinggi dibandingkan PGV-0, namun potensinya lebih rendah. Pada penelitian 
juga dievaluasi pelepasan hhistamin spontan dari sel mast.THPGV-0 dan PGV-0 
menunjukkan efek pelepasan histamin spontan yang rendah, atau  masih lebih 
rendah dari 10%.  
Kata kunci: tetrahidropentagamavunon-0, alergi, histamin, RBL-2H3   
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Introduction  
2,5-Bis(4-hydroxy-3-methoxybenzylidene) 
cyclopentanone (Fig. 1), also known as Penta-
gamavunon-0 (PGV-0), is a benzylidene 
cyclopentanone analog of curcumin. The 
compound was firstly synthesized for a number 
of purposes such the one made by Kodak in 
1961 for developing film-forming 
photosensitive polymers. The compound was 
reported possessing stronger pharmacological 
activities such as anti-inflammatory, 
antioxidative and antibacterial effects in 
compare to curcumin (Sardjiman, 2000). The 
compound also showed antiallergy effects in 
rat basophilic leukemia cell line and rat 
peritoneal mast cell in vitro. PGV-0 inhibited 
histamine release potently by altering some 
intracellular signaling events in mast cells, 
especially by blocking Ca2+ uptake into mast 
cells (Nugroho et al., 2009). Besides, PGV-0 
also inhibited the histamine release from the rat 
hind paw induced by compound 48/80.            
PGV-0 markedly decreased the rat paw edema, 
and prevented the loss of the histamine 
content and mast cell degranulation in skin 
tissue (Nugroho et al., 2010a). However,          
PGV-0 could not inhibit the contraction of 
isolated guinea pig trachea induced by 
histamine. PGV-0 significantly decreased the 
histamine accumulation in BALF to 30 % of 
the value of control group in asthmatic rats 
(Nugroho et al., 2010b). 
In the study of pharmacokinetics 
properties of PGV-0 in rats, intravenous 
injection of the compound at the dose of 20 or 
40 mg/kg BW resulted in erratic profile and 
low levels of the substance in blood. After the 
injection, the substance levels in blood 
decreased rapidly during 1-5 min, and followed 
by a slow elimination process (Nurshanti, 
2001). Besides, per oral administration of the 
compound as well as curcumin also resulted in 
erratic profile and low levels of the substance 
in blood. However, the Cmax of PGV-0 was 
higher than this of curcumin (Kustaniah, 2001). 
The biotransformation of PGV-0 was assumed 
to be similar to this of curcumin since the 
chemical structures of these compounds are 
similar. Curcumin   is  poorly absorbed   in  the  
 
intestine. There are facts that the 
biotransformation of curcumin is fast and 
could occur during absorption process in 
gastrointestinal tract. High degree of 
metabolism of curcumin also occurs in the liver 
and can be eliminated in the bile rapidly. Its 
facts suggest that only very low concentration 
of the substance was found in the body after 
ingestion. Besides, its metabolites, mainly 
glucuronated curcumin and tetrahydro-
curcumin (THC) serve as the available forms 
of curcumin in vivo (Pan et al., 1999). THC 
showed equal antiallergy effect in compare to 
the curcumin. Moreover the THC possessed 
more potent effects in several biological 
activities such as antioxidant, antidiabetes, anti-
inflammatory. THC has important roles in the 
biological effects of curcumin (Nugroho, 
2006).  
In the biotranformation of curcumin, 
tetrahydrocurcumin is one of the main 
metabolite of curcumin, and more stable than 
this of curcumin in buffer solutions of 
physiologic (pH 7.2) and basic pH at 37 °C 
(Pan et al., 1999). In addition, 
tetrahydrocurcumin has equal pharmacological 
activities in comparison to curcumin 
(Nugroho, 2006). For elimination process, 
THC was subsequently glucuronidated by 
UDP-glucuronosyl transferase yielding THC-
glucuronoside (Pan et al., 1999). According to 
these facts, tetrahydropentagamavunon-0 
(THPGV-0) is assumed to be a main 
metabolite product of biotransformation 
process of PGV-0 in the body. THPGV-0 was 
firstly synthesized by Ritmaleni and Simbara 
(2010). In this study, PGV-0 was converted to 
THPGV-0 by hydrogenation with Pd/C as a 
catalyst at room temperature. In present study, 
we investigated the antiallergy effect of 
THPGV-0 in comparison to PGV-0 in vitro. 
 
 
 
Figure 1. The chemical structure of tetrahydro-
pentagamavunon-0 (THPGV-0). 
Inhibitory effect of THPGV-0……….. 
Majalah Farmasi Indonesia, 21(4), 2010 244 
Methodology 
Materials  
Tetrahydropentagamavunon-0 (THPGV-0) 
was synthesized through two steps. Firstly, 
pentagamavunon-0 (PGV-0) was synthesized by 
reacting vanillin and cyclopentanon in acidic 
condition. Second step, the compound was 
converted to THPGV-0 by hydrogenation with 
Pd/C as a catalyst at room temperature (Ritmaleni 
and Simbara, 2010). DNP24-BSA as an antigen and 
monoclonal IgE against DNP24-BSA purified from 
supernatant in IgE producing hybridoma, were 
produced in Department of Pharmacology, School 
of Medicine Ehime University Japan. Eagle’s 
minimum essential medium (MEM) and antibiotics 
(combination of penicillin G sodium and 
streptomycin sulfate) were purchased from Gibco 
(Grand Island, NY, USA). Fetal calf serum was 
obtained from JRH Biosciences (Kansas, USA).  
Piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES) 
was purchased from Dojindo (Kumamoto, Japan), 
and o-phthalaldehyde was from Wako Pure 
Chemical Industires. (Osaka, Japan).   
  
Culture of RBL-2H3 cells 
The cells were cultured in MEM containing 
15% fetal calf serum and antibiotics (penicillin and 
streptomycin) in a flask in a humidified atmosphere 
(5% CO2) at 37 C as described by Barsumian et al. 
(1981). For the assay of histamine release, cells were 
seeded into 24-well culture plates at a density of 5 x 
105 cells/0.4 ml per each well. The cells were 
incubated overnight at 37 C. For DNP24-BSA 
experiments, the cells were sensitized with 0.5 
g/mL of monoclonal IgE. On the second day, the 
medium was removed, and the cells were washed 
twice with 500 L of PIPES buffer (119mM NaCl, 
5mM KCl, 25mM PIPES, 5.6mM glucose, 0.4mM 
MgCl2, 1mM CaCl2, 40mM NaOH, and 0.1 % BSA, 
pH 7.2), and preincubated for 10 min at 37 C after 
addition of 180 L PIPES buffer either without (as 
a negative control) or with the drug. After 10 min 
preincubation, 20 L of stimulant (200 ng/mL 
DNP24-BSA, 5 M thapsigargin, or 10 M 
ionomycin) were added to each well and the plate 
was incubated at 37 C for 30 min.  
 
Assay of histamine release 
Histamine released in the medium was 
measured by HPLC-fluorometry according to 
Yamatodani et al. (1985). After a 30 min incubation, 
the plates were centrifuged at 1,800 x g for 5 min 
and 50 l of the supernatant was mixed with 250 
L of 3% perchloric acid containing 5mM Na2-
EDTA. After addition of 30 L of 2 M KOH/1 M 
KH2PO4 and centrifugation at 10,000 x g for          
15 min at 4 C , 50 L of the supernatant was 
injected directly onto a column packed with TSKgel 
SP-2SW cation exchanger (Tosoh, Tokyo). For 
measuring the total histamine content in cells,            
350 L of PIPES buffer was added to 6 wells and 
the cells were then sonicated. Fifty microlitres cell 
homogenate was used for the histamine assay 
described above.  Histamine was eluted with 0.25 M 
potassium phosphate at a flow rate of 0.6 mL/min, 
and post-labeled with o-phthalaldehyde under 
alkaline conditions and detected using a F1080 
Fluorometer (Hitachi, Tokyo) at excitation and 
emission wavelengths of 360 and 450 nm, 
respectively.  
 
Data analysis 
The values were expressed as a percentage 
of net histamine release. The percent inhibition of 
histamine release was calculated according to the 
following equation : inhibition of histamine release 
(%) = [(histamine release in the absence of the test  
compound  –  histamine release in the presence of 
the test compound) /  histamine release in the 
absence of the test compound)] x 100. Spontaneous 
release (%) = (histamine content in the supernatant 
of unstimulated cells/total histamine content) x 100.  
The IC50 values are concentration of the 
compounds causing half maximal inhibitory effects 
on the histamine release from mast cells. All data 
were expressed as mean  SEM. One-way analysis 
of variance (ANOVA) followed by the least 
significant difference (LSD) test were used for 
statistical analyses. P-values less than 0.05 were 
considered significant. 
 
Result and Discussion 
Dinitrophenylated bovine serum 
albumin (DNP-BSA), an antigen was used to 
induce the histamine release from RBL-2H3 
cells, a tumor analog of mucosal mast cells. In 
the experiment, we evaluated the effects of 
various concentration of DNP-BSA on the 
histamine release. DNP-BSA could stimulate 
the histamine release in concentration-
dependent manner, even though at higher 
concentration tend to show lower effect as 
showed at concentration of 200 ng/mL. In the 
study, DNP-BSA at the concentration of 20 
ng/mL has showed a maximum effect by 
stimulating the histamine release by 33.07 2.79 
% (n=3). Based on this result, concentration of 
20 ng/mL was used for inducing the histamine 
release in the next experiments. 
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In the study, THPGV-0 showed a 
gradual inhibitory effect on histamine release 
from RBL-2H3 cells (Fig. 2a). The effect of 
THPGV-0 was concentration-dependent. At 
lower concentrations, THPGV-0 showed slight 
inhibitory effects on the histamine release 
(P>0.05). In contrast, at higher concentrations 
(30 and 100 M) the inhibitory effects of 
THPGV-0 increased progressively (P<0.05). 
Moreover, at concentration of 100 M, 
THPGV-0 strongly depleted the histamine 
release from RBL-2H3 cells by 96.10 0.51%. 
The IC50 value of THPGV-0 was 34.10 M. 
The maximum inhibitory effect (Emax) and 
IC50 values represent efficacy and potency of 
the compound, respectively.   
In the other side, PGV-0 also showed 
gradual inhibitory effects on histamine release 
from RBL-2H3 cells (Fig. 2b). The effect of 
PGV-0 was concentration-dependent. PGV-0 
obviously showed the inhibitory effect started 
at concentration of 3 M (P<0.05). At 
concentration of 100 M, PGV-0 suppressed 
the histamine release from RBL-2H3 cells by 
63.66 4.68%. The IC50 value of PGV-0 was 
23.79 M. 
We also observed the possibility of the 
spontaneous release from RBL-2H3 cells by 
THPGV-0 with a series of concentration              
(1-100 M). The effect was considered 
significant if THPGV-0 caused spontaneous 
histamine release of more than 10 %. All 
    
 
Figure 2. Effects of various concentrations (1-100 M) of tetrahydropentagamavunon-0  
(THPGV-0) (a) or pentagamavunon-0 (PGV-0) (b) on the histamine release from RBL-
2H3 cells induced by DNP-BSA 20 ng/mL. The data were representative of three-four 
independent experiments. 
 
Table I. Spontaneous histamine release from RBL-2H3 cells by THPGV-0 in absence of the 
antigen. (n = 3 – 4) 
 
Concentration ( M) 
of the compound 
Spontaneous histamine release (%) 
THPGV-0 PGV-0 
1 1.05 2.97 2.56 2.21 
3 1.13 2.10 2.96 2.85 
10 1.21 2.12 6.40 3.20 
30 6.13 7.12 8.62 0.49 
100 6.84 3.40 9.01 0.63 
(Thapsigargin 0.5 M) 74.30 7.10 
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concentrations of THPGV-0 as well as PGV-0 
showed low spontaneous histamine release, less 
than 10 % of the total histamine contained in 
RBL-2H3 cells (Table I). As a comparison, 
thapsigargin, a sesquiterpene lactone isolated 
from the plant Thapsia garginica (Patkar et al., 
1979), potently stimulated the histamine release 
from RBL-2H3 cells by 74.3 7.1%. 
Allergy reaction can be triggered by 
allergens, such as grass pollen, dust mite, 
certain foodstuffs or some drugs, that evoke 
the production of IgE type then attach mast 
cell via the high-affinity FcεRI receptors on the 
mast cell surface (Rang et al., 2003). DNP24-
BSA is a specific antigen for monoclonal IgE 
antibody. The antigen cross-link into IgE 
antibody molecules on FcεRI receptors to 
generate a series of intracellular signaling in 
mast cells. Finally, these phenomena trigger the 
granule exocytosis releasing histamine from 
mast cells (Metcalfe et al. 1997; Liu et al., 1980).  
In the case of curcumin, 
tetrahydrocurcumin (THC) serves as the 
available form of curcumin in vivo. 
Tetrahydrocurcumin is one of the main 
metabolite of curcumin, and more stable than 
this of curcumin in buffer solutions of 
physiologic (pH 7.2) and basic pH. at 37°C 
(Pan et al., 1999). THC showed an equal 
antiallergy effect in comparison to the 
curcumin. Moreover the THC possessed more 
potent effects in several biological activities 
such as antioxidant, antidiabetes, anti-
inflammatory. THC has important roles in the 
biological effects of curcumin (Nugroho, 
2006). For elimination process, THC was 
subsequently glucuronidated by UDP-
glucuronosyl transferase yielding THC-
glucuronoside (Pan et al., 1999). THPGV-0 is 
assumed to be a main metabolite of PGV-0. In 
the study of pharmacokinetics properties of 
PGV-0 in rats, the substance levels in blood 
decreased rapidly during 1-5 min, and followed 
by a slow elimination process after intravenous 
injection (Nurshanti, 2001). In addition, per 
oral administration of the compound as well as 
curcumin also resulted in erratic profile and 
low levels of the substance in blood 
(Kustaniah, 2001). Sugiyanto et al. (2003) 
reported that PGV-0 underwent phase 1 
biotransformation, and produced at least one 
metabolite. One metabolite was suspected as 
tetrahydropentagamavunon-0 (THPGV-0). 
Subsequently, the metabolites still possessing 
hydroxyl group underwent conjugation process 
(phase 2 biotransformation).  
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Figure 3. Comparison between the IC50 and Emax values of THPGV-0 with PGV-0. Both values 
represent potency and efficacy of the inhibitory effects of THPGV-0 and PGV-0. 
 
 
 
Agung Endro Nugroho 
Majalah Farmasi Indonesia, 21(4), 2010 247 
In vivo study, PGV-0 potently inhibited 
the histamine release from the rat hind paw 
induced by compound 48/80. In addition, 
PGV-0 could decrease the rat paw edema, and 
prevented the loss of the histamine content 
and mast cell degranulation in skin tissue 
(Nugroho et al., 2010a). PGV-0 did not 
influence the contraction of isolated guinea pig 
trachea induced by histamine, however, 
potently decreased the histamine accumulation 
in BALF to 30 % of the value of control group 
in asthmatic rats. In addition, PGV-0 
significantly prevented the histamine decrease 
in asthmatic rats to 37.8% trachea, and 34.2% 
in bronchus. However, PGV-0 did not succeed 
to prevent the histamine decrease in the lung 
of asthmatic rats (Nugroho et al., 2010b). PGV-
0 showed potent pharmacological effects in vivo 
such as anti-inflammatory and antiallergy, but it 
poorly was found in the blood. These facts 
indicate that THPGV-0 might have important 
roles in the biological effects of PGV-0 in vivo. 
There are only few studies about the 
pharmacological activities of THPGV-0. 
Agustina (2010) reported that THPGV-0 
showed antifungal activity on C. albicans. 
Simbara (2009) reported that the compound as 
well as PGV-0 showed DPPH free radical 
scavenger activity in vitro. The antioxidative 
activity of THPGV-0 on DPPH free radical 
was more potent than this of PGV-0 or 
vitamin E. In the case of tetrahydrocurcumin, 
its aromatic or phenolic hydroxy and -diketon 
moieties are assumed to have important roles 
in its antioxidative property (Sugiyama et al., 
1996; Priyadarsini et al., 2003). Suzuki et al. 
(2005) reported that the inhibitory effect of 
curcumin and its analogues on histamine 
release were closely related to its antioxidant 
properties. Free radicals derived from 
metabolites of unsaturated fatty acids 
participate in the induction of histamine release 
(Di Bello et al., 1998; Mannaioni et al., 1996). In 
present study, THPGV-0 at concentration of 
100 M strongly depleted the histamine release 
from RBL-2H3 cells a tumor analog of 
mucosal mast cells, by 96.10 0.51%. As a 
comparison, PGV-0 at the concentration of 
100 M inhibited the histamine release by 
63.66 4.68%. Maximum inhibitory effect of 
THPGV-0 is higher than this of PGV-0. These 
facts indicate THPGV-0 is stronger than PGV-
0 to inhibit the histamine release. However, the 
IC50 of THPGV-0 was higher than this of 
PGV-0 so the potency of THPGV-0 was less 
than this of PGV-0 (Fig. 3). These facts 
indicate that THPGV-0 has higher efficacy 
than this of PGV-0, however, THPGV-0 was 
less potent than this of PGV-0. Efficacy is 
capacity to produce a maximum effect, whereas 
potency is a function of drug concentration 
required for its specific effect (usually half of 
maximal effects) to occur. Modification of the 
chemical structure of PGV-0 due to its 
biotransformation process was suggested to 
influence its potency and efficacy. However, 
further investigation is needed to explain these 
phenomena. 
In the previous study, benzylidenecy-
clopentanone curcumin analogues including 
PGV-0 were investigated for their effects on 
viability of RBL-2H3 for certain time 
incubation of the compounds. In the case of 
PGV-0, treatment with various concentrations 
of the compound (1, 10, or 100 µM) for 30 min 
did not influence the viability of RBL-2H3 
cells, however, they markedly decreased the 
viability of the cells after 24 hours incubation 
in dose-dependent manner (Nugroho et al., 
2010c). 
 
Conclusion 
THPGV-0 succeeded to inhibit the 
histamine release from RBL-2H3 cells induced 
by DNP-BSA. THPGV-0 has higher efficacy 
than this of PGV-0, however, THPGV-0 was 
less potent than this of PGV-0. 
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